RPI-1 – 10 mg

Brand:
Cayman
CAS:
269730-03-2
Storage:
-20
UN-No:
De Minimis - 3077 / 9

RPI-1 is an ATP-dependent RET kinase inhibitor. It has been shown to selectively inhibit the anchorage-independent growth of NIH3T3 cells transformed by the ret/ptc1 oncogene with an IC50 value of 0.97 µM.{32109} In a spontaneously metastasizing lung carcinoma xenograft mouse model, daily oral treatment with RPI-1 was reported to significantly reduce spontaneous lung metastases.{32108}  

 

Available on backorder

SKU: 20384 - Category:

Description

An ATP-dependent Ret kinase inhibitor that prevents metastasis both in vitro and in vivo


Formal name: 1,3-dihydro-3-[(4-hydroxyphenyl)methylene]-5,6-dimethoxy-2H-indol-2-one

Synonyms: 

Molecular weight: 297.3

CAS: 269730-03-2

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|Other Receptor Tyrosine Kinases||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Migration & Metastasis||Research Area|Cancer|Cell Signaling